Experimental drug shown to 'significantly' slow progression of brain cancer


A new experimental drug was found to "significantly" reduce the progression of brain cancer, Reuters reported.
Vorasidenib, created by Servier Group, a private drug developer, was shown to slow the progression of brain tumors by an average of over 16 months, per Bloomberg. The results of the 331-patient study were published June 4 in The New England Journal of Medicine.
The study's lead author, Ingo Mellinghoff, described this as "a very big finding," adding that the drug "is the first molecularly targeted treatment for diffuse glioma." Vorasidenib specifically works on Grade 2 gliomas, which are "progressive, malignant brain tumors" that are "more common in adults but can also occur in children and teenagers," according to Reuters. The drug blocks a specific enzyme mutated in low-grade gliomas, keeping them from progressing and postponing the need for further treatment like chemotherapy.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"What you just heard is a trial that was well done and well thought out: to use an oral, targeted, well-tolerated therapy to see if we could delay the use of our standard chemotherapy and radiation," Wake Forest Baptist Health's Dr. Glenn Lesser commented at an American Society of Clinical Oncology briefing. "The results are quite striking and they're statistically highly significant, and more importantly, they're clinically very, very significant."
Servier Group is working to get the drug approved by the Food & Drug Administration for use in the U.S.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
5 explosively funny cartoons about the 4th of July
Cartoons Artists take on liberty and justice for all, a terrifying firework, and more
-
Jeff in Venice: a "triumph of tackiness"?
In the Spotlight Locals protest as Bezos uses the city as a 'private amusement park' for his wedding celebrations
-
Sudoku medium: July 5, 2025
The Week's daily medium sudoku puzzle
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Climate change can impact our gut health
Under the radar The gastrointestinal system is being gutted
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
Children's breakfast cereals are getting more unhealthy
Under the radar Your kids may be starting their day with more than a spoonful of sugar
-
The marvelous powers of mucus
The Explainer It's snot just a pesky cold symptom
-
'Wonder drug': the potential health benefits of creatine
The Explainer Popular fitness supplement shows promise in easing symptoms of everything from depression to menopause and could even help prevent Alzheimer's
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots